

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/134158 A1

(43) International Publication Date
10 August 2017 (10.08.2017)

(51) International Patent Classification:
C07K 16/28 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:
PCT/EP2017/052239

(22) International Filing Date:
2 February 2017 (02.02.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/290,875 3 February 2016 (03.02.2016) US

(71) Applicant: AMGEN RESEARCH (MUNICH) GMBH
[DE/DE]; Staffelseestrasse 2, 81477 Munich (DE).

(72) Inventors: RAUM, Tobias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). MUENZ, Markus; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BROZY, Johannes; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). KUFER, Peter; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). HOFFMANN, Patrick; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). FRIEDRICH, Matthias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RATTEL, Benno; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BOGNER, Pamela; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). WOLF, Andreas; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2,

81477 Munich (DE). POMPE, Cornelius; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agents: WEINZIERL, Gerhard et al.; Schiweck Weinzierl Koch, Landsberger Strasse 98, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PSMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

(57) Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3_E chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.



WO 2017/134158 A1